FRUZAQLA^® (fruquintinib) resources for healthcare professionals

Access Support

FRUZAQLA Access Guide

Discover ordering details for FRUZAQLA

Download access guide

Sample Letter of Medical Necessity

Request insurance coverage for FRUZAQLA by filling out this template for your patients.

Download letter

Sample Letter of Medical Appeals

Use this template to appeal an insurance denial for FRUZAQLA

Download letter

Takeda Oncology Here2Assist® Enrollment Form

An interactive PDF to help your patients get started with Takeda Oncology Here2Assist®

Download the PDF

Clinical Support

FRUZAQLA Dosing Guide

Get information on FRUZAQLA dosing

Download dosing guide

Dosing Calendar

Help your patients track their treatment schedule

Access dosing calendar

NCCN Leave Behind

Discover the NCCN recommendations for FRUZAQLA

Download leave behind

FRUZAQLA MOA Brochure

Explore even more about how FRUZAQLA works with this downloadable PDF.

Download brochure

Patient Profile: Barbara*

Learn about Barbara, a patient with mCRC and liver metastasis^†

Download patient profile

Patient Profile: Mark*

Learn about Mark, a patient with mCRC presenting with myelosuppression

Download patient profile

Metastatic colorectal cancer ICD-10 codes

We help support the reimbursement process by providing ICD-10 codes.

This list includes commonly used ICD-10 codes for metastatic colorectal cancer:

C18.0 Malignant neoplasm of cecum
C18.2 Malignant neoplasm of ascending colon
C18.3 Malignant neoplasm of hepatic flexure
C18.4 Malignant neoplasm of transverse colon
C18.5 Malignant neoplasm of splenic flexure
C18.6 Malignant neoplasm of descending colon
C18.7 Malignant neoplasm of sigmoid colon
C18.8 Malignant neoplasm of overlapping sites of colon
C18.9 Malignant neoplasm of colon, unspecified
C19 Malignant neoplasm of rectosigmoid junction

C20 Malignant neoplasm of rectum
C21.8 Malignant neoplasm of overlapping sites of rectum, anus and anal canal
Z12.12 Encounter for screening for malignant neoplasm of colon
Z12.12 Encounter for screening for malignant neoplasm of rectum
C78.5 Secondary malignant neoplasm of large intestine and rectum
C78.6 Secondary malignant neoplasm of retroperitoneum and peritoneum
D37.4 Neoplasm of uncertain behavior of colon
D37.5 Neoplasm of uncertain behavior of rectum

Request a Rep

Fill out a contact form to be contacted by a Takeda representative.

Request a call

Takeda Oncology Here2Assist^® Patient Support Program

We're here to help your patients with their coverage, financial, and educational resource needs.

Get program details

Resources to Support Your Patients

Find resources to support your patients taking FRUZAQLA.

Get patient resources

*Hypothetical patient. Individual patient results may vary.

^†FRUZAQLA should not be used in patients with severe hepatic impairment (total bilirubin >3 times ULN and any AST). Please see full Prescribing Information for more information.¹

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Hypertension occurred in 49% of 911 patients with mCRC treated with FRUZAQLA, including Grade 3-4 events in 19%, and hypertensive crisis in three patients (0.3%). Do not initiate FRUZAQLA unless blood pressure is adequately controlled. Monitor blood pressure weekly for the first month and at least monthly thereafter as clinically indicated. Initiate or adjust anti-hypertensive therapy as appropriate. Withhold, reduce dose, or permanently discontinue FRUZAQLA based on severity of hypertension.

Hemorrhagic Events including serious, fatal events can occur with FRUZAQLA. In 911 patients with mCRC treated with FRUZAQLA, 6% of patients experienced gastrointestinal hemorrhage, including 1% with a Grade ≥3 event and 2 patients with fatal hemorrhages. Permanently discontinue FRUZAQLA in patients with severe or life-threatening hemorrhage. Monitor the International Normalized Ratio (INR) levels in patients receiving anticoagulants.

Infections. FRUZAQLA can increase the risk of infections, including fatal infections. In 911 patients with mCRC treated with FRUZAQLA, the most common infections were urinary tract infections (6.8%), upper respiratory tract infections (3.2%) and pneumonia (2.5%); fatal infections included pneumonia (0.4%), sepsis (0.2%), bacterial infection (0.1%), lower respiratory tract infection (0.1%), and septic shock (0.1%). Withhold FRUZAQLA for Grade 3 or 4 infections, or worsening infection of any grade. Resume FRUZAQLA at the same dose when the infection has resolved.

Gastrointestinal Perforation occurred in patients treated with FRUZAQLA. In 911 patients with mCRC treated with FRUZAQLA, 1.3% experienced a Grade ≥3 gastrointestinal perforation, including one fatal event. Permanently discontinue FRUZAQLA in patients who develop gastrointestinal perforation or fistula.

Hepatotoxicity. FRUZAQLA can cause liver injury. In 911 patients with mCRC treated with FRUZAQLA, 48% experienced increased ALT or AST, including Grade ≥3 events in 5%, and fatal events in 0.2% of patients. Monitor liver function tests (ALT, AST, and bilirubin) before initiation and periodically throughout treatment with FRUZAQLA. Temporarily hold and then reduce or permanently discontinue FRUZAQLA depending on the severity and persistence of hepatotoxicity as manifested by elevated liver function tests.

Proteinuria. FRUZAQLA can cause proteinuria. In 911 patients with mCRC treated with FRUZAQLA, 36% experienced proteinuria and 2.5% of patients experienced Grade ≥3 events. Monitor for proteinuria before initiation and periodically throughout treatment with FRUZAQLA. For proteinuria ≥2g/24 hours, withhold FRUZAQLA until improvement to ≤Grade 1 proteinuria and resume FRUZAQLA at a reduced dose. Discontinue FRUZAQLA in patients who develop nephrotic syndrome.

Palmar-Plantar Erythrodysesthesia (PPE) occurred in 35% of 911 patients treated with FRUZAQLA, including 8% with Grade 3 events. Based on severity of PPE, withhold FRUZAQLA and then resume at the same or reduced dose.

Posterior Reversible Encephalopathy Syndrome (PRES), a syndrome of subcortical vasogenic edema diagnosed by characteristic finding on MRI, occurred in one of 911 patients treated with FRUZAQLA. Perform an evaluation for PRES in any patient presenting with seizures, headache, visual disturbances, confusion, or altered mental function. Discontinue FRUZAQLA in patients who develop PRES.

Impaired Wound Healing. In 911 patients with mCRC treated with FRUZAQLA, 1 patient experienced a Grade 2 event of wound dehiscence. Do not administer FRUZAQLA for at least 2 weeks prior to major surgery. Do not administer FRUZAQLA for at least 2 weeks after major surgery and until adequate wound healing. The safety of resumption of FRUZAQLA after resolution of wound healing complications has not been established.

Arterial Thromboembolic Events. In 911 patients with mCRC treated with FRUZAQLA, 0.8% of patients experienced an arterial thromboembolic event. Initiation of FRUZAQLA in patients with a recent history of thromboembolic events should be carefully considered. In patients who develop arterial thromboembolism, discontinue FRUZAQLA.

Allergic Reactions to FD&C Yellow No. 5 (Tartrazine) and No. 6 (Sunset Yellow FCF). FRUZAQLA 1 mg capsules contain FD&C Yellow No. 5 (tartrazine), which may cause allergic-type reactions (including bronchial asthma) in certain susceptible persons. FRUZAQLA 1 mg contains FD&C Yellow No. 6 (sunset yellow FCF), which may cause allergic reactions.

Embryo-Fetal Toxicity. Based on findings in animal studies and its mechanism of action, FRUZAQLA can cause fetal harm when administered to pregnant women. Advise pregnant women of the potential risk to a fetus.

ADVERSE REACTIONS

The most common adverse reactions (incidence ≥20%) following treatment with FRUZAQLA included hypertension, palmar-plantar erythrodysesthesia (hand-foot skin reactions), proteinuria, dysphonia, abdominal pain, diarrhea, and asthenia.

DRUG INTERACTIONS

Avoid concomitant administration of FRUZAQLA with strong or moderate CYP3A inducers.

USE IN SPECIFIC POPULATIONS

Lactation: Advise women not to breastfeed during treatment with FRUZAQLA and for 2 weeks after the last dose.

Females and Males of Reproductive Potential

Pregnancy Testing: Verify pregnancy status of females of reproductive potential prior to initiating FRUZAQLA.
Contraception: Females of childbearing potential and males with female partners of childbearing potential should use effective contraception during treatment and for 2 weeks after the last dose of FRUZAQLA.
Infertility: Advise females of reproductive potential that FRUZAQLA may cause post-implantation loss.

To report SUSPECTED ADVERSE REACTIONS, contact Takeda Pharmaceuticals at 1-844-662-8532 or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see FRUZAQLA (fruquintinib) full Prescribing Information.

FRUZAQLA^® (fruquintinib) resources for healthcare professionals

Access Support

FRUZAQLA Access Guide

Sample Letter of Medical Necessity

Sample Letter of Medical Appeals

Takeda Oncology Here2Assist® Enrollment Form

Clinical Support

FRUZAQLA Dosing Guide

Dosing Calendar

NCCN Leave Behind

FRUZAQLA MOA Brochure

Patient Profile: Barbara*

Patient Profile: Mark*

Metastatic colorectal cancer ICD-10 codes

Request a Rep

Takeda Oncology Here2Assist^® Patient Support Program

Resources to Support Your Patients

IMPORTANT SAFETY INFORMATION AND INDICATION

WARNINGS AND PRECAUTIONS

ADVERSE REACTIONS

DRUG INTERACTIONS

USE IN SPECIFIC POPULATIONS

INDICATION

Access Support

FRUZAQLA Access Guide

Sample Letter of Medical Necessity

Sample Letter of Medical Appeals

Takeda Oncology Here2Assist® Enrollment Form

Clinical Support

FRUZAQLA Dosing Guide

Dosing Calendar

NCCN Leave Behind

FRUZAQLA MOA Brochure

Patient Profile: Barbara*

Patient Profile: Mark*

Metastatic colorectal cancer ICD-10 codes

Request a Rep

Takeda Oncology Here2Assist® Patient Support Program

Resources to Support Your Patients

IMPORTANT SAFETY INFORMATION AND INDICATION

Takeda Oncology Here2Assist^® Patient Support Program